HER2-positive breast cancer is a type of aggressive cancer marked by uncontrolled production of breast cells. About 20% of women and men diagnosed with breast cancer have HER2-positive cancer, specifically.
Currently, oncologists treat HER2-positive breast cancer patients with surgery, radiation, chemotherapy, or targeted treatments like Herceptin (trastuzumab), Kadcyla (Ado-trastuzumab-emtansine), Perjeta (Pertuzumab), and Tykerb (Lapatinib).
These targeted treatments work by interfering with the protein that signals breast cell production, and they’re often used in conjunction with chemotherapy, which undoubtedly, can be a very arduous treatment process.
Comments are closed.